The impact of novel treatment modalities on the therapeutic approach of cardiovascular diseases

Angiology

Volumn 60, Issue 1, 2009, Pages 5-7

  Paraskevas, Kosmas I ^a   Psathas, Chrisovalantis ^a   Dragios, Theodoros ^a   Chatzis, Dimitrios G ^a   Mikhailidis, Dimitri P ^b   Kyriakides, Zenon S ^a  

^a RED CROSS HOSPITAL   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASCULOTROPIN;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CEREBROVASCULAR DISEASE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; EDITORIAL; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; REVASCULARIZATION; SALVAGE THERAPY;

ANGIOGENESIS MODULATING AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CELL TRANSPLANTATION; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; GENE THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TREATMENT OUTCOME;

EID: 59149099572     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708328923     Document Type: Editorial

References (38)

1. Al Mheid I., Quyyumi AA Cell therapy in peripheral arterial disease. Angiology. 2008 ; 59: 705-716.
2. Poredos P., Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007 ; 58: 309-315.
3. Paraskevas KI, Papas TT, Pavlidis P., Bessias N., Andrikopoulos V. The importance of conservative measures in peripheral arterial disease: an update. Angiology. 2008 ; 59: 529-533.
4. Mikroulis D., Papanas N., Maltezos E., Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol. 2007 ; 5: 195-209.
5. Paraskevas KI, Mikhailidis DP Angiogenesis: a promising treatment option for peripheral arterial disease. Curr Vasc Pharmacol. 2008 ; 6: 78-80.
6. Lin JW, Sheu WH, Lee WJ, et al. Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease. Angiology. 2007 ; 58: 420-428.
7. Rohovsky S., Kearney M., Pieczek A., et al. Elevated levels of basic fibroblast growth factor in patients with limb ischemia. Am Heart J. 1996 ; 132: 1015-1019.
8. Ozawa T., Kato K., Sanada H., et al. Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia-a case report. Angiology. 2006 ; 57: 235-239.
9. Higashi Y., Kimura M., Hara K., et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilatation in patients with limb ischemia. Circulation. 2004 ; 109: 1215-1218.
10. Koshikawa M., Shimodaira, Yoshioka T., et al. Therapeutic angiogenesis by bone marrow implantation of critical hand limb ischemia in patients with peripheral arterial disease: a pilot study. Curr Med Res Opin. 2006 ; 22: 793-798.
11. Tateishi-Yuyama E., Matsubara H., et al, and the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002 ; 360: 427-435.
12. Paraskevas KI, Stathopoulos V., Mikhailidis DP Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008 ; 6: 237-239.
13. Tsiara S., Elisaf M., Mikhailidis DP Early vascular benefits of statin therapy. Curr Med Res Opin. 2003 ; 19: 540-556.
14. Robinson JG Simvastatin: present and future perspectives. Expert Opin Pharmacother. 2007 ; 8: 2127-2159.
15. Jaumdally JR, Varma C., Lip GY Statin therapy in South-Asian patients: clinical implications beyond lipid lowering ? Expert Opin Pharmacother. 2007 ; 8: 1235-1243.
16. Paraskevas KI, Liapis CD, Hamilton G., Mikhailidis DP Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery ? Eur J Vasc Endovasc Surg. 2006 ; 32: 286-293.
17. Paraskevas KI, Hamilton G., Mikhailidis DP Statins: an essential component in the management of carotid artery disease. J Vasc Surg. 2007 ; 46: 373-386.
18. Sarafidis PA, Kanaki AI, Lasaridis AN Effects of statins on blood pressure: a review of the experimental and clinical evidence. Curr Vasc Pharmacol. 2007 ; 5: 155-161.
19. Horwich TB, MacLellan WR Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007 ; 8: 3061-3068.
20. Efthimiadis A. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises? Angiology. 2008 ; 59 (2 suppl). 62S - 64S.
21. Filippatos TD, Mikhailidis DP Statins and heart failure. Angiology. 2008 ; 59 (2 suppl). 58S - 61S.
22. Isma N., Barani J., Mattiasson I., Lindblad B., Gottsater A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology. 2008 ; 59: 542-548.
23. Kamishirado H., Inoue T., Sakuma M., et al. Effect of statins on restenosis after stent implantation. Angiology. 2007 ; 58: 55-60.
24. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des. 2007 ; 13: 3622-3636.
25. Amarenco P. Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opin Pharmacother. 2007 ; 8: 2789-2797.
26. Athyros VG, Kakafika AI, Tziomalos K., Papageorgiou AA, Karagiannis A. Statins for the prevention of first or recurrent stroke. Curr Vasc Pharmacol. 2008 ; 6: 124-133.
27. Sallustio F., Diomedi M., Centonze D., Stanzione P. Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors. Curr Vasc Pharmacol. 2007 ; 5: 259-265.
28. Dilaveris P., Giannopoulos G., Riga M., Synetos A., Stefanadis C. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol. 2007 ; 5: 227-237.
29. Ashton JC, Smith PF Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol. 2007 ; 5: 175-185.
30. Andrikopoulos GK, Tzeis S. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism. Angiology. 2008 ; 59 (2 suppl). 44S - 48S.
31. Biscione F., Pignalberi C., Totteri A., Messina F., Altamura G. Cardiovascular effects of omega-3 free fatty acids. Curr Vasc Pharmacol. 2007 ; 5: 163-172.
32. Tziomalos K., Athyros VG, Karagiannis A., Mikhailidis DP Omega-3 Fatty acids: how can they be used in secondary prevention ? Curr Atheroscler Rep. 2008 ; 10: 510-517.
33. Leaf A., Kang JX, Xiao YF Fish oil fatty acids as cardiovascular drugs. Curr Vasc Pharmacol. 2008 ; 6: 1-12.
34. Yamaoka-Tojo M., Tojo T., Izumi T. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol. 2008 ; 6: 271-281.
35. Yu J., Weiwer M., Linhardt RJ, Dordick JS The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol. 2008 ; 6: 204-217.
36. Tomita N., Morishita R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Des. 2004 ; 10: 797-803.
37. Athyros VG, Kakafika AI, Tziomalos K., Karagiannis A., Mikhailidis DP Antisense technology for the prevention or treatment of cardiovascular diseases: the next blockbuster ? Expert Opin Investig Drugs. 2008 ; 17: 969-972.
38. Crooke ST Antisense strategies. Curr Mol Med. 2004 ; 4: 465-487.